RecruitingEarly Phase 1NCT07122076

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Sponsor

Grit Biotechnology

Enrollment

10 participants

Start Date

Aug 22, 2025

Study Type

INTERVENTIONAL

Conditions

Autoimmune Diseases

Summary

This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called GT719 Injection for people with autoimmune diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.